Four patients had experienced an acute-rejection episode before the hematological disorder: two had steroid-sensitive acute rejection, which was treated with steroid pulses (Patients 1 and 6), one patient had a combined cellular and humoral rejection, which required steroid pulses, plasma exchanges, and rituximab (Patient 7), and one patient, who had received anti-IL2R blockers as an induction therapy, experienced steroid-resistant acute rejection, which was treated with steroid pulses and polyclonal antibodies (Patient 5). This evidence concerns the gene IL2RA and hematologic disorder.